Cited by 207Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver Diseases and Immunity

The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Díaz, Luis Antonio, Arab, Juan Pablo, Louvet, Alexandre, Bataller, Ramón, Arrese, Marco·2023·Nature Reviews Gastroenterology & Hepatology

DOI 10.1038/s41575-023-00822-y

Open this paper in CoChat — free account

Abstract

Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the leading causes of chronic liver disease worldwide. NAFLD and ALD share pathophysiological, histological and genetic features and both alcohol and metabolic dysfunction coexist as aetiological factors in many patients with hepatic steatosis. A diagnosis of NAFLD requires the exclusion of significant alcohol consumption and other causes of liver disease. However, data suggest that significant alcohol consumption is often under-reported in patients classified as having NAFLD and that alcohol and metabolic factors interact to exacerbate the progression of liver disease. In this Review, we analyse existing data on the interaction between alcohol consumption and metabolic syndrome as well as the overlapping features and differences in the pathogenesis of ALD and NAFLD. We also discuss the clinical implications of the coexistence of alcohol consumption, of any degree, in patients with evidence of metabolic derangement as well as the use of alcohol biomarkers to detect alcohol intake. Finally, we summarize the evolving nomenclature of fatty liver disease and describe a recent proposal to classify patients at the intersection of NAFLD and ALD. We propose that, regardless of the presumed aetiology, patients with fatty liver disease should be evaluated for both metabolic syndrome and alcohol consumption to enable better prognostication and a personalized medicine approach.

Integrity signals

Registry

Crossref · 10.1038/s41575-023-00822-y

Cites

253 of 253 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation
Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R. M., Tymeson, H. D., Venkateswaran, V., Tapp, A. D., Forouzanfar, M. H., Salama, J. S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31310-2 · Cited by 3,524
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citation
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citation
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citation
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 5×
“Alcohol intake can be broadly classified as mild (up to 20 g (women) and 30 g (men) per day), moderate (21–39 g (women) and 31–59 g (men) per day), or heavy (≥40 g (women) and ≥60 g (men) per day) 9 .”
BackgroundInfluential
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002

Show all 252 references

Research works printed but not linked: 2

Hajduch, E., Lachkar, F., Ferré, P. & Foufelle, F. Roles of ceramides in non-alcoholic fatty liver disease. J. Clin. Med. Res. 10, 792 (2021).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).

Sorted by citations

Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V. G., Mehta, N., Parikh, N. D., Abou‐Alfa, G. K., Singal, A. G., & Yang, J. D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 359
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease
Arab, J. P., Díaz, L. A., Rehm, J. T., Im, G. Y., Arrese, M. A., Kamath, P. S., Lucey, M. R., Mellinger, J. L., Thiele, M. S., Thursz, M. R., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.028 · Cited by 193
Self-citation
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study
Israelsen, M., Torp, N., Johansen, S., Hansen, C. D., Hansen, E. D., Thorhauge, K., Hansen, J. K., Villesen, I., Bech, K., Wernberg, C., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00443-0 · Cited by 174
From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research
Hsu, C. L., & Loomba, R. S. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00985-1 · Cited by 123
Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes
Díaz, L. A., Fuentes–López, E., Idalsoaga, F. J., Ayares, G., Corsi, Ó., Arnold, J., Cannistra, M., Vio, D., Márquez‐Lomas, A., Ramírez, C., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.006 · Cited by 107
Self-citation
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 88
Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Danpanichkul, P., Díaz, L. A., Suparan, K., Tothanarungroj, P., Sirimangklanurak, S., Auttapracha, T., Blaney, H. L., Sukphutanan, B., Pang, Y., Kongarin, S., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0835 · Cited by 85
Self-citation
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Fan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 92
Prevalence of at‐risk MASH , M et ALD and alcohol‐associated steatotic liver disease in the general population
Schneider, C. V., Schneider, K. M., Raptis, A. A., Huang, H. Y. R., Trautwein, C., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17958 · Cited by 70
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
Tamaki, N., Kimura, T., Wakabayashi, S., Umemura, T., Kurosaki, M., Loomba, R. S., & Izumi, N. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18015 · Cited by 69
Endogenous ethanol production in health and disease
Meijnikman, A. S., Nieuwdorp, M., & Schnabl, B. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00937-w · Cited by 76
Food inequity and insecurity and MASLD: burden, challenges, and interventions
Zelber‐Sagi, S., Carrieri, P., Pericàs, J. M., Wajcman, D. I., Younossi, Z. M., & Lazarus, J. V. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00959-4 · Cited by 63
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 72
Self-citation
Alcohol-related liver disease: A global perspective
Castro‐Narro, G., Díaz, L. A., Ortega, E. K., Garín, M. F. B., Reyes, E. C., Delfin, P. S. M., Arab, J. P., & Bataller, R. A. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101499 · Cited by 58
Self-citation
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Díaz, L. A., Lazarus, J. V., Fuentes–López, E., Idalsoaga, F. J., Ayares, G., Desaleng, H., Danpanichkul, P., Cotter, T. G., Dunn, W., Francisco Barrera, M., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00649-x · Cited by 55
Self-citation
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments
Israelsen, M. E., Thorhauge, K. H., Andersen, P., Johansen, S., Schnefeld, H. L., Bech, K., Hansen, J. K., Torp, N., Jensen, E. L., Hansen, E. D., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.007 · Cited by 49
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease
Díaz, L. A., Winder, G. S., Leggio, L., Bajaj, J. S., Bataller, R. A., & Arab, J. P. (2023) · Hepatology · doi:10.1097/hep.0000000000000645 · Cited by 47
Self-citation
The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)
Danpanichkul, P., Suparan, K., Díaz, L. A., Fallon, M. B., Chen, V. L., Namsathimaphorn, K., Rakwong, K., Inkongngam, T., Kaeosri, C., Kalligeros, M., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70072 · Cited by 43
Self-citation
Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry
Ochoa‐Allemant, P., Serper, M., Wang, R. X., Tang, H., Ghandour, B., Khan, S., & Mahmud, N. (2024) · Hepatology · doi:10.1097/hep.0000000000000914 · Cited by 42
Metabolic and alcohol-associated liver disease (MetALD): a representation of duality
Leal-Lassalle, H., Estévez‐Vázquez, O., Cubero, F. J., & Nevzorova, Y. A. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00014-8 · Cited by 50
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Díaz, L. A., Alazawi, W., Agrawal, S., Arab, J. P., Arrese, M. A., Idalsoaga, F. J., Barreyro, F. J., Gadano, A. C., Marciano, S., Morales, J. M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.035 · Cited by 49
Self-citation
Structure characteristics of a novel pectic polysaccharide from Fructus Corni and its protective effect on alcoholic fatty liver
Bai, H.-X., Gao, Y., Wang, S., Ma, G.-Y., Zhao, W., Li, X., Wang, Y., Nong, Q.-N., Wang, Y., Tan, J. H., et al. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.123153 · Cited by 40
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
Wu, H., Chen, J., Guo, S., Deng, J., Zhou, Z., Zhang, X., Qi, T., Yu, F., & Yang, Q. L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2500099 · Cited by 42
Ionizable polymeric micelles (IPMs) for efficient siRNA delivery
Zhou, Z., Yu, F., Jiang, M., Yao, Z., Wang, J., Pan, F., Feng, R., Zhao, C., Ma, Y., Zhou, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55721-w · Cited by 42
The burden of liver disease in Latin America
Díaz, L. A., Villota‐Rivas, M., Francisco Barrera, M., Lazarus, J. V., & Arrese, M. A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101175 · Cited by 42
Self-citation
MetALD: Does it require a different therapeutic option?
Marek, G. W., & Malhi, H. (2024) · Hepatology · doi:10.1097/hep.0000000000000935 · Cited by 41
Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly
Danpanichkul, P., Suparan, K., Ng, C. H., Dejvajara, D., Kongarin, S., Panpradist, N., Chaiyakunapruk, N., Muthiah, M. D., Chen, V. L., Huang, D. Q., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101020 · Cited by 37
Self-citation
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, M., Uribe, J., Olvares, N., Huerta, P., Cabrera, D., & Romero‐Gómez, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101501 · Cited by 38
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Gao, B., Arab, J. P., Liangpunsakul, S., Ding, W., Szabó, G., Mehal, W. Z., Wang, H., He, Y., Stärkel, P., Llorente, C., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100319 · Cited by 43
Self-citation
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 34
Self-citation
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Díaz, L. A., Thiele, M. S., Louvet, A., Lee, B. P., Ajmera, V. H., Tavaglione, F., Hsu, C. L., Huang, D. Q., Pose, E., Bataller, R. A., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01120-5 · Cited by 33
Self-citation
Innate-like T cells in liver disease
Yang, A. Y.-P., Wistuba‐Hamprecht, K., Greten, T. F., & Ruf, B. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.05.008 · Cited by 36
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Canivet, C. M., Boursier, J., & Loomba, R. S. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1785196 · Cited by 29
Recent advances of lipid droplet-targeted AIE-active materials for imaging, diagnosis and therapy
Yuan, S., & Zhao, E. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116802 · Cited by 29
Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy
Magyar, C. T. J., O'Kane, G. M., Aceituno, L., Li, Z., Vogel, A., Bruix, J., Mazzaferro, V., & Sapisochín, G. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00857 · Cited by 27
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Díaz, L. A., Ajmera, V. H., Arab, J. P., Huang, D. Q., Hsu, C. L., Lee, B. P., Louvet, A., Thiele, M. S., Tavaglione, F., Tincopa, M. A., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.017 · Cited by 28
Self-citation
Advancements in molecular disassembly of optical probes: a paradigm shift in sensing, bioimaging, and therapeutics
Saczuk, K., Dudek, M., Matczyszyn, K., & Deiana, M. (2024) · Nanoscale Horizons · doi:10.1039/d4nh00186a · Cited by 26
Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: A Bidirectional Association Based on Endothelial Dysfunction
Ktenopoulos, N., Sagris, Μ., Gerogianni, M., Pamporis, K., Apostolos, A., Balampanis, K., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910595 · Cited by 27
Combined Insults of a MASH Diet and Alcohol Binges Activate Intercellular Communication and Neutrophil Recruitment via the NLRP3-IL-1β Axis in the Liver
Babuta, M., Nagesh, P. T., Datta, A. A., Remotti, V., Zhuang, Y., Mehta, J., Lami, F., Wang, Y., & Szabó, G. (2024) · Cells · doi:10.3390/cells13110960 · Cited by 27
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
Jokinen, M. J., & Luukkonen, P. K. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.003 · Cited by 27
Moving diagnosis of liver fibrosis into the community
Pose, E., Piano, S. S., Thiele, M. S., Fabrellas, N., Tsochatzis, E. A., & Ginès, P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.026 · Cited by 24
Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice
Cho, Y. E., Kim, Y. S., Kim, S.-J., Lee, H., & Hwang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015489 · Cited by 24
Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD)
Dyńka, D., Rodzeń, Ł., Rodzeń, M., Łojko, D., Kraszewski, S., Ibrahim, A., Hussey, M., Deptuła, A., Grzywacz, Ż., Ternianov, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164857 · Cited by 28
The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside
Shen, X., Yang, H., Yang, Y., Zhu, X., & Sun, Q. (2024) · MedComm · doi:10.1002/mco2.664 · Cited by 21
Regulatory mechanisms of the probiotic-targeted gut–liver axis for the alleviation of alcohol-related liver disease: a review
Yang, F., Li, X., Sun, J. Y., Pang, X., Sun, Q., & Lu, Y. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2455954 · Cited by 22
Alcohol-Metabolizing Enzymes, Liver Diseases and Cancer
Liu, T., Zhang, F., Feng, Y., Han, P., & Gao, Y. (2025) · Seminars in Liver Disease · doi:10.1055/a-2551-3320 · Cited by 19
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)
Díaz, L. A., Tavaglione, F., Mittal, N., Bettencourt, R., Amangurbanova, M., Johnson, A., Aguado, D. M., Tincopa, M. A., Loomba, R. K., Khan-Riches, A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000718 · Cited by 19
Self-citation
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
Liu, C., Seto, W., & Yu, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10699-x · Cited by 18
Emerging Role of Phosphatidylethanol Testing in Clinical Practice for the Identification of Steatotic Liver Disease Subtypes: Is This the New Standard?
Loomba, R. S., Hagström, H., & Díaz, L. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.07.007 · Cited by 17
Self-citation
Unveiling the cancer risk nexus of the steatotic liver
Kim, J., & Seki, E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.017 · Cited by 17
Leptin limits hepatic lipid accumulation and inflammation via vagal activation of the JAK2-STAT3/AMPK pathway
Xiong, S., Wang, Q., Chen, Y., Du, H., & Zhao, Y. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109748 · Cited by 17
Acidic polysaccharide CP-2 from Dioscoreae Rhizoma ameliorated acute alcoholic liver injury through the gut-liver axis and AMPK/PPAR pathway
Xie, Y., Tao, M., Yan, X., Fan, X., Bayoude, A., Lu, Y., Zhao, S., Yu, B., & Li, R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143145 · Cited by 16
Perspective on alcohol-induced organ damage via autophagy-dependent cellular changes
Bakheet, A., Anbazhagan, M., Barve, S. S., Dasarathy, S., Dickinson, J. J., Ding, W., Donohue, T. M., Gopal, T., Gukovskaya, A. S., Kharbanda, K. K., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103879 · Cited by 17
Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks
Martínez‐Urbistondo, D., Pérez-Díaz-del-Campo, N., Landecho, M. F., & Martínez, J. A. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00560-5 · Cited by 20
MicroRNAs in metabolic dysfunction‐associated diseases: Pathogenesis and therapeutic opportunities
Ma, N., Tan, J., Chen, Y., Liu, Y., Li, M., & He, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202401464r · Cited by 21
Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm
Brennan, P., Zelber‐Sagi, S., Allen, A. M., Dillon, J. F., & Lazarus, J. V. (2023) · Gut · doi:10.1136/gutjnl-2023-330771 · Cited by 17
Increased mortality from alcohol use disorder, alcohol‐associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021
Danpanichkul, P., Duangsonk, K., Tham, E. K. J., Tothanarungroj, P., Auttapracha, T., Prasitsumrit, V., Sim, B., Tung, D., Barba, R., Wong, R. J., et al. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15516 · Cited by 15
Self-citation
Promoting In Vivo NIR-II Fluorescent Imaging for Lipid in Lipid Metabolism Diseases Diagnosis
Wang, K., Wen, X., Chen, X.-Y., Yue, Y., Yang, Y., Zhu, H., Wang, M., & Jiang, H. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05676 · Cited by 14
Gut Bacteria in Alcohol-Associated Liver Disease
Yang, Y., & Schnabl, B. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.008 · Cited by 14
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
Danpanichkul, P., Duangsonk, K., Kalligeros, M., Fallon, M. B., Vuthithammee, C., Pan, C., Saokhieo, P., Derrick, W. P., Pang, Y., Chen, V. L., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18473 · Cited by 15
Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study
Chen, H., Chen, S., Liu, D., Liang, Y., Li, H., Bao, Y., Zhu, Z., Dong, K., Li, W., Liang, F., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101884 · Cited by 14
Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
Danpanichkul, P., Pang, Y., Mahendru, T., Tothanarungroj, P., Díaz, L. A., Arab, J. P., Jatupornpakdee, P., Muthiah, M. D., Duangsonk, K., Choi, W.-M., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0169 · Cited by 14
Self-citation
Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases
Wang, Y., Ren, J., & Ren, S. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00406.2023 · Cited by 14
Review article: Current indications and selection criteria for early liver transplantation in severe alcohol‐associated hepatitis
Ramírez, C., Blaney, H. L., Kubánek, N., Díaz, L. A., Loomba, R. S., Skladaný, Ľ., & Arab, J. P. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17948 · Cited by 13
Self-citation
MASLD: a disease in flux
Allen, A. M., Arab, J. P., & Wong, V. W. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00990-5 · Cited by 13
Self-citation
Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta‐analysis
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Gaviraghi, A., Motta, L., Gobbi, F. G., Tilg, H., Byrne, C. D., & Targher, G. (2024) · Liver International · doi:10.1111/liv.16101 · Cited by 11
Towards more consistent models and consensual terminology in preclinical research for steatotic liver disease
Meijnikman, A. S., Fondevila, M. F., Arrese, M. A., Kisseleva, T., Bataller, R. A., & Schnabl, B. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.025 · Cited by 12
Self-citation
Young Adults and Alcohol-Associated Liver Cancer: Incidence and Death from 2000 to 2021
Danpanichkul, P., Pang, Y., Díaz, L. A., Arab, J. P., Hwang, S. Y., Dejvajara, D., Suresh, V. V., Suenghataiphorn, T., Wannaphut, C., Suparan, K., et al. (2025) · Cancers · doi:10.3390/cancers17040609 · Cited by 11
Self-citation
Alcohol‐Attributable Cancer: Update From the Global Burden of Disease 2021 Study
Danpanichkul, P., Pang, Y., Díaz, L. A., White, T. M., Sirimangklanurak, S., Auttapracha, T., Suparan, K., Syn, N. L. X., Jatupornpakdee, P., Saowapa, S., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70163 · Cited by 12
Self-citation
RNF2 Modulates Lipid Metabolism and Inflammation in Alcohol-associated Liver Disease by Interacting with USP7
Qi, Y., Fang, Q., Chen, Z., Chen, L., & Du, J. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.111290 · Cited by 11
Liver injury protection of Artemisia stechmanniana besser through PI3K/AKT pathway
Tian, C.-B., Qin, M.-L., Qian, Y.-L., Qin, S.-S., Shi, Z.-Q., Zhao, Y., & Luo, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118590 · Cited by 10
Periodontal disease and cirrhosis: current concepts and future prospects
Hudson, D., Ayares, G., Taboun, Z., Malhi, G., Idalsoaga, F., Mortuza, R., Souyet, M., Ramirez-Cadiz, C., Díaz, L. A., Arrese, M., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2024-100140 · Cited by 12
Self-citation
The Effects of Recreational and Pharmaceutical Substance Use on Oral Microbiomes and Health
Esposito, M. M., Kalinowski, J., & Mikhaeil, M. (2024) · Bacteria · doi:10.3390/bacteria3030015 · Cited by 9
A charge reversal nano-assembly prevents hepatic steatosis by resolving inflammation and improving lipid metabolism
Wang, H., Su, S., An, X., Xu, Y., Sun, J., Zhen, M., Wang, C., & Bai, C. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.11.023 · Cited by 9
US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020
Banini, B. A., Chauhan, S., Amatya, A., Dashti, F., Zahrawi, K., Zahrawi, F. M., Mehal, W. Z., & McKee, S. A. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15515 · Cited by 9
Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis
Vanlerberghe, B. T. K., Dumitrascu, C., den Eede, N. V., Neels, H. M., van Malenstein, H., Gevers, T. J. G., Kramer, M., Melkebeke, L. V., Masclee, A., de Boer, D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101433 · Cited by 9
Hepatic IκBζ promotes alcohol-associated liver disease and acute hepatitis by enhancing CXCL1-Mediated neutrophil infiltration
Liu, L., Qian, S., Li, W., Dong, S., Ya, R., He, Y., Huang, H., Chen, Y., Ma, N., Hao, Y., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.022 · Cited by 9
Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis
Rahman, A. T., Choi, J., Kyung, W., Kang, S., Lee, S., & Jon, S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123576 · Cited by 10
Innate immune sensing of dietary alcohol ignites inflammation to drive alcohol-related disease
Jang, Y., Bae, H., Oh, S., Yu, G., Bae, H., Nguyen, M. Q., Mall, R., Fu, M., Ghosh, A., Lee, J., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea3979 · Cited by 10
Antidiabetic Effects of Methanolic Extract of Trigonella foenumgraecum Seeds in Diabetic Rats
(2023) · Pakistan Veterinary Journal · doi:10.29261/pakvetj/2023.108 · Cited by 9
Impact of alcohol use on liver disease outcomes
Desalegn, H., Díaz, L. A., Rehm, J. T., & Arab, J. P. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000192 · Cited by 9
Self-citation
An Activatable Semiconducting Nanoprobe for Early and Accurate Diagnosis of Liver Injury
Li, F., Wu, S., Li, K., Zhu, J., He, S., & Tian, H. (2024) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.4c00022 · Cited by 8
Epidemiology of Alcohol-Associated Liver Disease Including Increasing Burden in Young Adults and Females Especially Since Covid-19 Pandemic
Zhang, W., & Wong, R. J. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.001 · Cited by 8
Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease
Desalegn, H., Farias, R., Hudson, D., Idalsoaga, F. J., Cabrera, D., Díaz, L. A., & Arab, J. P. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.30 · Cited by 8
Self-citation
Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
Zerehpooshnesfchi, S., Lonardo, A., Fan, J.-G., Elwakil, R., Tanwandee, T., Altarrah, M. Y., Örmecı, N., & Eslam, M. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.04 · Cited by 8
Liver stiffness measurement by magnetic resonance elastography predicts cirrhosis and decompensation in alcohol-related liver disease
Chen, J., Xu, P., Kalutkiewicz, K. J., Sheng, Y., Warsame, F., Tahboub-Amawi, M.-A., Li, J., Wang, J., Venkatesh, S. K., Ehman, R. L., et al. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04479-2 · Cited by 8
MetALD: Genetic Factors and Clinical Outcomes
Israelsen, M. E., Trépo, E., Krag, A. A., & Stender, S. (2025) · Seminars in Liver Disease · doi:10.1055/a-2630-0952 · Cited by 7
Modulation of gut microbiota by crude gac aril polysaccharides ameliorates diet-induced obesity and metabolic disorders
Lu, T.-J., Chiou, W.-C., Huang, H., Pan, H., Sun, C.-Y., Way, T., & Huang, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133164 · Cited by 11
Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut–liver crosstalk for clinical translation
Benedé‐Ubieto, R., Estévez‐Vázquez, O., Acar, R., Leal-Lassalle, H., Gutierrez, A. H., Redondo‐Urzainqui, A., Iborra, S., Odintsova, V. E., Tyakht, A., Herranz, J. M., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2631834 · Cited by 7
The global epidemiology of alcohol-associated liver disease
Danpanichkul, P., Idalsoaga, F. J., Murray, F., Arab, J. P., & Díaz, L. A. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000947 · Cited by 6
Self-citation
A next generation probiotic, Bacteroides xylanisolvens
Chen, C., Nie, Q., Lin, Q., Zou, J., & Nie, S. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105173 · Cited by 5
Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-Associated Liver Disease
Torosian, K., Díaz, L. A., Tesfai, K., Wu, W., Cooper, K. M., Devuni, D., Mohamed, K., Lim, N., Rajan, A., Cheung, A. C., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.02.001 · Cited by 5
Self-citation
Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017–2020
Wang, P., Xia, B., & Wang, S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1505970 · Cited by 6
Implications of liver fibrosis in clinical trials
Jahagirdar, V., Rama, K., Cabrera, D., Idalsoaga, F. J., Díaz, L. A., Arrese, M. A., & Arab, J. P. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102112 · Cited by 7
Self-citation
Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease
Zhang, Z., Lu, J., Chen, M., Dai, L., Xiang, Y., Liu, Z., Cao, Y., Sheng, W., Li, C., Song, D., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02784-3 · Cited by 6
Burden of liver cancer and underlying etiologies in China from 1990 to 2021: A systematic analysis from the Global Burden of Disease Study 2021
Li, M., He, H., Zhao, X., Guan, M., Khattab, N. M., Elshishiney, G., You, H., & Hu, Y. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003828 · Cited by 4
Alcohol use disorder is a chronic disease
Gilpin, N. W., & Molina, P. E. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70230 · Cited by 4

Authors: Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M.
Affiliations: Pontificia Universidad Católica de Chile (CL)
Western University (CA)
Inserm (FR)
Corresponding author: Arrese, Marco
ORCID: Díaz, Luis Antonio
Arab, Juan Pablo
Louvet, Alexandre
Arrese, Marco
Venue: Nature Reviews Gastroenterology & Hepatology
Publisher: Springer Science and Business Media LLC
Published: 2023-08-15
Volume: 20
Issue: 12
Pages: 764-783
ISSN: 1759-5045 (ISSN-L)
1759-5053
DOI: 10.1038/s41575-023-00822-y
OpenAlex: W4385851156
Semantic Scholar: f457122280dbd0b72d6e068cbffa2b2fe281bb04
Cited by: 207
References: 252
Citations by year: 2026: 58 · 2025: 75 · 2024: 63 · 2023: 11
FWCI: 8.06
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Gastroenterology & Hepatology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA021908, U01AA020821)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, alcoholic liver disease, metabolic syndrome, hepatic steatosis, alcohol consumption, alcohol biomarkers, disease classification, pathogenesis, chronic liver disease
MeSH terms: Alcohol Drinking, Ethanol, Humans, Biomarkers, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks